Crystal Research Associates (www.crystalra.com) released a new Executive Informational Overview on CardioComm Solutions, Inc. (EKG-TSX.V), a company specializing in software engineering for information management systems and the integration of bio-monitoring devices for the cardiac and telemedicine markets. The full 60-page report, which details CardioComm's innovative cardiac monitoring products, market opportunities, software platforms, additional products and technologies, competition, and other key fundamentals, is available at www.crystalra.com. CardioComm Solutions, Inc. specializes in software engineering of information management systems and integration of bio-monitoring devices for the cardiac and telemedicine markets. The Company’s integrated electrocardiogram (ECG) and arrhythmia monitoring products and services enable patients, medical professionals, and healthcare experts to quickly and easily manage patient information and ECG recordings in a secure, reliable environment from anywhere in the world—specifically to record, view, analyze, and store patients’ ECGs for diagnosis and treatment of cardiac disorders. Rated as the best enabling technology for cardiac rhythm monitoring in 2012 by Frost & Sullivan, CardioComm Solutions’ technology is used in a number of software and hardware products dedicated to improving the quality of life for anyone who has been diagnosed with, or who may be at risk for, cardiovascular disease. The Company recently introduced a new handheld ECG recording device, the HeartCheck™ PEN ECG, which represents the first in-home, consumer-targeted health monitoring technology for over-the-counter (OTC) markets in the past 30 years. The HeartCheck™ devices (which also include a prescription HeartCheck™ Handheld ECG Monitor) are supported by software programs and patent-pending “SMART Monitoring services,” which the Company has developed to enable 24/7 patient monitoring and objective medical interpretation, with the capacity for integrating ECG reporting into existing electronic medical records (EMRs), among other innovative features. Please view report for applicable disclosures. http://www.crystalra.com/research-library/cardiocomm-solutions-inc/

1. .
• A 60-page Executive Informational
Overview® (EIO) written by
Crystal Research Associates on CardioComm
Solutions, Inc. is available at
www.crystalra.com.
• Covers a range of topics:
o CardioComm’s cardiac monitoring
products
o Market opportunities
o Software platforms
o Additional products and technologies
o Competition
o …and other key fundamentals.
New Independent Equity Research

2. .
• Our Executive Informational Overview® (EIO) presents a crystal
clear, detailed report on a company in a manner that is easily
understood by the Wall Street financial community.
• It details a company’s product/technology/service offerings,
market size(s), key intellectual property, leadership, growth
strategy, competition, risks, financial statements, key events, and
other fundamental information.
• It is free of investment ratings, target prices, and forward-looking
financial models.
• Complete risks and disclosures are included within each EIO.
• Our trademarked EIOs are exclusively written by experienced,
award-winning analysts at Crystal Research Associates, LLC.
What is an EIO?

3. .
Excerpts from our EIO on
CardioComm Solutions, Inc.
(EKG-TSX.V)
THE FIRST FDA-CLEARED, HANDHELD, OVER-
THE-COUNTER ECG MONITOR FOR PATIENT
DIAGNOSIS AND MANAGEMENT

4. .
Overview of CardioComm Solutions
• Information management systems and bio-monitoring
devices for the cardiac and telemedicine markets
• Electrocardiogram (ECG) and arrhythmia monitoring
products and services enable quick and easy
management of patient information
o ECG recordings from
anywhere in the world
o Record, view, analyze,
and store patients’
ECGs for diagnosis and
treatment of cardiac
disorders

5. .
• Recently introduced a handheld
ECG recording device called
the HeartCheck™ PEN ECG
o the first in-home, consumer-
targeted health monitoring technology
for OTC markets in the past 30 years.
• HeartCheck™ is supported by software programs and patent-
pending “SMART Monitoring services”
o Enables 24/7 patient monitoring and objective medical interpretation
o Capacity for integrating ECG reporting into existing electronic
medical records (EMRs)
Products and Services

6. .
• Heart disease affects people of every race and is the leading
cause of death worldwide.
• In the U.S., the CDC estimates that approximately 715,000
heart attacks and 795,000 strokes occur each year.
o Strokes kill someone in the U.S. every four minutes, on average.
• Roughly 50% of deaths from heart attacks happen before
the patient has a chance to seek help.
By providing accurate and immediate cardiac data,
patient monitoring technologies such as CardioComm’s
could increase the likelihood of surviving a severe
cardiac event.
Market Opportunities

7. .
• The remote and wireless patient
monitoring market has significant
growth potential.
• The U.S. leads the world in
spending for remote cardiac
monitoring.
• According to research from
iSuppli Corp., part of global
information provider IHS Inc.
(IHS-NYSE), this market had a
value in the U.S. of $686 million
as of 2011, which is forecast to
expand by 27% to reach $867
million in 2016.
Data Source: IHS iSuppli’s March 4, 2013, press release
Market Opportunities
Source: IHSInMedica Research, February2012.
MillionsofU.S.Dollars
FORECASTOF U.S.MARKETFORREMOTECARDIAC MONITORINGSERVICES
($MM)

8. .
• Technology was rated as “the best enabling technology for
cardiac rhythm monitoring” in 2012 by Frost & Sullivan
Awards and Recognition

9. .
To read the entire 60-page EIO on
CardioComm Solutions Inc. (EKG-TSX.V) or
find information on other companies under
our coverage, please visit
www.crystalra.com.

10. .
Crystal Research Associates, LLC (www.crystalra.com) is an independent research firm that has
provided institutional-quality research on small- and mid-cap companies for the past decade. We
are led by veteran Wall Street sell-side analyst Jeffrey Kraws, who is well known by the
international financial media for his years of work on Wall Street and for providing consistent
award-winning analyses and developing long-term relationships on both the buy-side and sell-
side. He has been consistently ranked among the Top Ten Analysts for pharmaceutical stock
performance in the world for almost two decades as well as ranked as the Number One Stock
Picker in the world for pharmaceuticals by Starmine and for estimates from Zacks. Additionally,
Mr. Kraws has been 5-Star ranked for top biotechnology stock performance by Starmine.
About Us
Corporate Headquarters:
880 Third Avenue, 6th Floor
New York, NY 10022
Office: (212) 851-6685
Fax: (609) 395-9339
Satellite Office Location:
2500 Quantum Lakes Drive, Suite 203
Boynton Beach, FL 33426
Office: (561) 853-2234
Fax: (561) 853-2246
Jeffrey J. Kraws
CEO, Crystal Research Associates